Sales of Champix, a medication to treat nicotine addiction, have jumped eightfold in the past two years as more smokers attempt to kick their habits, Yonhap News Agency reported.

Sales of the Pfizer product rose to KRW 42 billion (EUR 35 million) in 2016 from 24 billion the year before, when sales increased fourfold, Yonhap said. Champix accounts for more than 80 per cent of the anti-smoking therapy market in Korea, the news agency said.